Suven Life Sciences Limited

This study tested a new drug called ropanicant in 41 adults with moderate to severe major depression. Researchers wanted to see if the drug is safe and if it helps reduce depression symptoms. The study was open-label, meaning everyone knew they were getting the drug, and it laste…

This study tested a new drug called ropanicant in 214 adults with major depression. Participants received one of two doses or a placebo for 6 weeks. The goal was to see if the drug reduces depression symptoms better than a placebo, using standard rating scales.

This early-stage study tested a new drug called SUVN-I6107 in 64 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo as a single dose or multiple doses. Researchers also checked for changes in brain activity using …